We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of Sequential Cord Blood Transplants

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00299767
First Posted: March 7, 2006
Last Update Posted: May 11, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Karen Ballen, Massachusetts General Hospital
  Purpose
The purpose of this study is to determine the safety of sequential cord blood transplantation (2 cord blood units) for patients who have diseases that are capable of being cured by allogeneic stem cell transplant but do not have a matched family or volunteer unrelated donor.

Condition Intervention Phase
Lymphoma Leukemia Multiple Myeloma Myelodysplastic Syndrome Procedure: sequential cord blood transplantation Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Sequential Cord Blood Transplants

Resource links provided by NLM:


Further study details as provided by Karen Ballen, Massachusetts General Hospital:

Primary Outcome Measures:
  • To evaluate the 100-day transplant-related (non-relapse) mortality, including relapse-related mortality associated with Grade 4 toxicity. [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • To evaluate the 6 month transplant related (non-relapse) mortality. [ Time Frame: 3 years ]
  • To evaluate the days to neutrophil engraftment (ANC > 500). [ Time Frame: 3 years ]
  • To evaluate the days of platelet engraftment (platelet count > 20K unsupported). [ Time Frame: 3 years ]
  • To evaluate the risk of acute and chronic graft versus host disease. [ Time Frame: 3 years ]
  • To evaluate percent donor chimerism - contribution of each cord unit. [ Time Frame: 3 years ]
  • To evaluate relapse rate.
  • To evaluate overall survival.
  • To evaluate transfusion support needed to cord blood transplant recipients. [ Time Frame: 3 years ]

Enrollment: 21
Study Start Date: May 2003
Study Completion Date: May 2009
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: sequential cord blood transplantation
    Infused on Day 0
Detailed Description:
Eligible patients will receive conditioning therapy with fludarabine 30 mg/m2/day x 6 days, melphalan 100 mg/m2/day x 1 day, rabbit antithymocyte globulin 1.5 mg/kg/day x 4 days. GVHD prophylaxis will consist of cyclosporine starting on day -1 and mycophenolate mofetil starting on day 0. Sequential cord blood units will be infused on Day 0.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Disease Status: NHL, HD, or MM refractory to chemotherapy or relapsed; CLL Rai Stage III/IV, or lymphocyte doubling time of 6 months, or Stage I/II resistant to 2 chemotherapy regimens; AML or ALL in second or subsequent remission or in first remission with adverse cytogenetics or antecedent hematologic disorder
  • Estimated disease-free survival of less than one year
  • ECOG performance status of 0, 1, 2
  • Lack of 6/6 or 5/6 HLA matched related or 6/6 matched unrelated donor, or a donor is not available within the time frame necessary to perform a potentially curative stem cell transplant
  • 4/6 or greater HLA A, B, CRB1 cord blood units with a combined nucleated cell dose from of > 3.7 x 10(7) NC/kg

Exclusion Criteria:

  • Cardiac disease: symptomatic congestive hearth failure or RVG or echocardiogram determined left ventricular ejection fraction of < 45%, active angina pectoris, or uncontrolled hypertension
  • Pulmonary Disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease, or corrected DLCO of < 50%
  • Renal disease: serum creatinine > 2.0 mg/dl
  • Hepatic disease: serum bilirubin > 2.0 mg/dl (except in the case of Gilbert's syndrome), SGPT or SGOT > 3 x normal
  • Neurologic disease: symptomatic leukoencephalopathy, active DNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation
  • HIV antibody or Hepatitis B surface antigen positivity
  • Uncontrolled infection
  • Pregnancy or breast-feeding mother
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00299767


Locations
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02116
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Investigators
Principal Investigator: Karen Ballen, M.D. Massachusetts General Hospital, Harvard University
Principal Investigator: Joseph Antin, M.D. Dana Farber Cancer Institute, Harvard Univeristy
Principal Investigator: David Avigan, M.D. Beth Israel Deaconess Medical Center
  More Information

Responsible Party: Karen Ballen, Director, Leukemia Program, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00299767     History of Changes
Other Study ID Numbers: 03-061
First Submitted: March 3, 2006
First Posted: March 7, 2006
Last Update Posted: May 11, 2016
Last Verified: May 2016

Additional relevant MeSH terms:
Multiple Myeloma
Myelodysplastic Syndromes
Preleukemia
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bone Marrow Diseases
Precancerous Conditions